{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:27:51Z","timestamp":1793838471047,"version":"4.6.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10637-026-01628-w","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:36:15Z","timestamp":1781872575000},"page":"354-358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database"],"prefix":"10.1007","volume":"44","author":[{"given":"Connor","family":"Frey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"8","key":"1628_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40265-020-01302-2","volume":"80","author":"A Lee","year":"2020","unstructured":"Lee A, Duggan S, Deeks ED (2020) Cemiplimab: a review in advanced cutaneous squamous cell carcinoma. Drugs 80(8):813\u2013819. https:\/\/doi.org\/10.1007\/s40265-020-01302-2","journal-title":"Drugs"},{"key":"1628_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2026.116596","volume":"238","author":"C Robert","year":"2026","unstructured":"Robert C, G\u00e9rard E, Lanoy E et al (2026) Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: results from the French study TOSCA. Eur J Cancer 238:116596. https:\/\/doi.org\/10.1016\/j.ejca.2026.116596","journal-title":"Eur J Cancer"},{"issue":"3","key":"1628_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/antib13030059","volume":"13","author":"C Frey","year":"2024","unstructured":"Frey C, Etminan M (2024) Adverse events of PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: an analysis of the FDA adverse events database. Antibodies (Basel) 13(3):59. https:\/\/doi.org\/10.3390\/antib13030059","journal-title":"Antibodies (Basel)"},{"issue":"36","key":"1628_CR4","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"issue":"1","key":"1628_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/imr.13249","volume":"318","author":"RS Goodman","year":"2023","unstructured":"Goodman RS, Jung S, Balko JM, Johnson DB (2023) Biomarkers of immune checkpoint inhibitor response and toxicity: challenges and opportunities. Immunol Rev 318(1):157\u2013166. https:\/\/doi.org\/10.1111\/imr.13249","journal-title":"Immunol Rev"},{"issue":"1","key":"1628_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/pharma4010001","volume":"4","author":"C Frey","year":"2025","unstructured":"Frey C (2025) Hepatobiliary adverse events associated with pembrolizumab: a pharmacovigilance study from the FDA adverse event reporting system (FAERS) database. Pharmacoepidemiol Drug Saf 4(1):1. https:\/\/doi.org\/10.3390\/pharma4010001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"0","key":"1628_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1120009X.2025.2561969","volume":"0","author":"C Frey","year":"2013","unstructured":"Frey C (2013) Characterizing pulmonary adverse events associated with the immune checkpoint inhibitor avelumab: a FAERS-based pharmacovigilance study from 2013 to 2024. J Chemother 0(0):1\u20135. https:\/\/doi.org\/10.1080\/1120009X.2025.2561969","journal-title":"J Chemother"},{"issue":"6","key":"1628_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"15","key":"1628_CR9","doi-asserted-by":"publisher","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","volume":"145","author":"CJ Beavers","year":"2022","unstructured":"Beavers CJ, Rodgers JE, Bagnola AJ et al (2022) Cardio-oncology drug interactions: a scientific statement from the American Heart Association. Circulation 145(15):e811\u2013e838. https:\/\/doi.org\/10.1161\/CIR.0000000000001056","journal-title":"Circulation"},{"issue":"1","key":"1628_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/imr.13240","volume":"318","author":"J Gong","year":"2023","unstructured":"Gong J, Neilan TG, Zlotoff DA (2023) Mediators and mechanisms of immune checkpoint inhibitor-associated myocarditis: insights from mouse and human. Immunol Rev 318(1):70\u201380. https:\/\/doi.org\/10.1111\/imr.13240","journal-title":"Immunol Rev"},{"issue":"9","key":"1628_CR11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/eurheartj\/ehaf682","volume":"47","author":"JE Salem","year":"2026","unstructured":"Salem JE, Ajrouche A, Rozes A, Pinto S, De Rycke Y, Tubach F (2026) Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study. Eur Heart J 47(9):1014\u20131030. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf682","journal-title":"Eur Heart J"},{"issue":"16_suppl","key":"1628_CR12","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.2024.42.16_suppl.2643","volume":"42","author":"AR Naqash","year":"2024","unstructured":"Naqash AR, Abushukair HM, Alghamdi E et al (2024) Triple M overlap syndrome (TMOS): evaluating immune checkpoint inhibitor-related overlap syndrome of myocarditis, myositis and myasthenia gravis using an international pharmacovigilance database. J Clin Oncol 42(16_suppl):2643\u20132643. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2643","journal-title":"J Clin Oncol"},{"issue":"1","key":"1628_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/imr.13257","volume":"318","author":"BS Allais","year":"2023","unstructured":"Allais BS, Fay CJ, Kim DY, Semenov YR, LeBoeuf NR (2023) Cutaneous immune-related adverse events from immune checkpoint inhibitor therapy: moving beyond \u201cmaculopapular rash.\u201d Immunol Rev 318(1):22\u201336. https:\/\/doi.org\/10.1111\/imr.13257","journal-title":"Immunol Rev"},{"issue":"4","key":"1628_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/ddg.15638","volume":"23","author":"JN Pruessmann","year":"2025","unstructured":"Pruessmann JN, Pruessmann W, Sadik CD (2025) Research in practice: immune checkpoint inhibitor related autoimmune bullous dermatosis. JDDG J Dtsch Dermatol Ges 23(4):441\u2013445. https:\/\/doi.org\/10.1111\/ddg.15638","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"3","key":"1628_CR15","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.chest.2020.11.027","volume":"159","author":"T Johkoh","year":"2021","unstructured":"Johkoh T, Lee KS, Nishino M et al (2021) Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors. Chest 159(3):1107\u20131125. https:\/\/doi.org\/10.1016\/j.chest.2020.11.027","journal-title":"Chest"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01628-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01628-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01628-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:06:13Z","timestamp":1793837173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01628-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01628-w","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval and patient consent were not required as the U.S. FDA previously collected all data utilized in this study.","order":1,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}